While tamoxifen, a SERM, which also binds to and inhibits ChEH, is prescribed to both pre- and post-menopausal women with ER + breast cancer, aromatase inhibitors are used to treat postmenopausal women with ER + breast cancer. Here, ESR1 is linked to breast carcinoma.